Horizon Pharma gets U.K. marketing authorization for DUEXIS Horizon Pharma announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted marketing authorization for DUEXIS for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug associated gastric and/or duodenal ulcers. Horizon is seeking to license rights to DUEXIS in Europe to one or more commercial partners.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Horizon Pharma to host special shareholder meeting Special shareholder meeting to consider and seek shareholder approval of the acquisition of Vidara Therapeutics, will be held in Deerfield, IL on September 18 at 9 am.